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 Abstract 
 Objective:  Renal function is often compromised in severe obesity. A true measurement of 
glomerular filtration rate (GFR) is unusual, and how estimation formulae (EstForm) perform in 
such individuals is unclear.  We characterized renal function and hemodynamics in severely 
obese individuals, assessing the reliability of EstForm.  Methods:  We measured GFR (mGFR) by 
iohexol plasma clearance, renal plasma flow (RPF) by  123 I-ortho-iodo-hippurate, basal and 
stimulated vascular renal indices, endothelium-dependent and -independent vasodilation us-
ing flow-mediated dilation (FMD) as well as metabolic and hormonal profile in morbid, oth-
erwise healthy, obese subjects.  Results:  Compared with mGFR, the better performing EstForm 
was CKD-EPI (5.3 ml/min/1.73 m 2 bias by Bland-Altman analysis). mGFR was directly related 
with RPF, total and incremental glucose AUC, and inversely with PTH and h8 cortisol. Patients 
with mGFR below the median shown significantly higher PTH and lower vitamin D3. Basal or 
dynamic renal resistive index, FMD, pulse wave velocity were not related with mGFR. In an 
adjusted regression model, renal diameter and plasma flow remained related with mGFR
(R 2 = 0.67), accounting for 15% and 21% of mGFR variance, respectively.  Conclusions:  CKD-EPI
formula should be preferred in morbid obesity ;  glucose increments during oral glucose toler-
ance test correlate with hyperfiltration; RPF and diameter are independent determinants of 
mGFR; slightly high PTH values, frequent in obesity, might influence mGFR. 
 © 2016 The Author(s)
Published by S. Karger GmbH, Freiburg 
 Received: January 4, 2016 
 Accepted: May 16, 2016 
Published online: October 5, 2016
 Anna Solini, MD PhD 
 Department of Clinical and Experimental Medicine 
 University of Pisa 
 56126 Pisa, Italy 
 anna.solini  @  med.unipi.it 
www.karger.com/ofa
 DOI: 10.1159/000446965 
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-
tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribu-
tion for commercial purposes as well as any distribution of modified material requires written permission.
 Edoardo Vitolo and Eleonora Santini equally contributed to this article. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ita
 d
i P
isa
   
   
   
   
   
   
   
   
   
   
   
   
 
13
1.
11
4.
81
.2
29
 - 
11
/7
/2
01
6 
11
:1
8:
50
 A
M
311Obes Facts 2016;9:310–320
 DOI: 10.1159/000446965 
 Vitolo et al.: Metabolic and Hormonal Determinants of Glomerular Filtration Rate and 
Renal Hemodynamics in Severely Obese Individuals 
www.karger.com/ofa
© 2016 The Author(s). Published by S. Karger GmbH, Freiburg
 Introduction 
 Obesity is an independent risk factor and a powerful predictor of chronic kidney disease 
(CKD) and end-stage renal disease  [1–3] . Among the mechanisms underlying obesity-asso-
ciated renal pathology, abnormalities of sodium sensitivity, insulin resistance, and hyperal-
dosteronism are recognized  [4, 5] . 
 A fast glomerular filtration rate (GFR) decline, even remaining above the usual threshold 
marking the definition of CKD (60 ml/min/1.73 m 2 ), is a powerful determinant of cardiovas-
cular (CV) disease in the general population and in high-risk individuals  [6, 7] . Therefore, an 
accurate assessment of renal function is strongly recommended in the clinical practice to 
better define the individual renal and CV risk profile. 
 Renal injury associated with obesity shows a high prevalence of albuminuria and inflam-
mation-driven glomerular lesions  [8, 9] . Moreover, a relative glomerular hyperfiltration is 
frequent  [10, 11] , and obesity-related glomerulopathy itself can be considered a maladaptive 
response to hyperfiltration and albuminuria  [12] . Hyperglycemia is a major determinant of 
hyperfiltration in diabetes  [13] , while data obtained in morbid obesity are scanty. 
 In the clinical practice, a range of bedside tools, based on mathematical formulae including 
age, gender, serum creatinine and sometimes body weight, are used to estimate GFR. Though 
each of these formulae has its own limitations, they can be reliably used in the normal popu-
lation, with a reported better accuracy of the CKD-EPI than the MDRD study equation for higher 
GFR levels  [14, 15] . Given the high prevalence of obesity in the western countries, an obvious 
question concerns the reliability of these formulae in obese patients  [16] and whether or not 
they require correction for body weight confounders like total and lean weight and body surface 
area  [17, 18] . Studies validating these formulae in morbidly obese individuals are lacking.
 Doppler ultrasonography, routinely used to characterize CKD, allows to identify macro- 
and microvascular abnormalities, with intra-parenchymal arterial waveform offering infor-
mation on arteriolosclerosis and interstitial fibrosis  [19] . Among ultrasonographic indicators 
of renal hemodynamics, renal resistive index (RI) has been related with BMI  [20] , but no 
study have so far related RI and its variation to a vasodilatory stimulus to the filtration 
function in severely obese individuals. In this view, it is interesting to assess by exploring the 
relationship between GFR and renal vascular reactivity whether or not the true measurement 
can be reliably replaced by the estimation value. Therefore, we designed a protocol to compare 
estimated GFR (eGFR) and ultrasonographic assessment of renal vasculature with true 
measurements of renal filtration and flow in a group of severely obese individuals, relating 
these observations with their metabolic and hormonal patterns.
 Patients and Methods 
 Patients  
 50 morbidly obese individuals (BMI > 40 kg/m 2 ) participating in a clinical program to evaluate their eligi-
bility for bariatric surgery were recruited in the years 2013–2014 in the section of Metabolic Medicine in our 
hospital. Exclusion criteria were age > 60 years, diabetes (excluded by a standard oral glucose tolerance test 
(OGTT) performed 1 week before the study day), essential hypertension, systemic inflammatory diseases, serum 
creatinine above the normal range, and presence of micro- or macroalbuminuria (excluded by nephelometric 
analysis on a 24-hour urine collection performed 2 weeks before the study day). The protocol was approved by 
the Ethics Committee of the University of Pisa (n.3463/2011). All participants signed an informed consent.
 After an overnight fast, patients underwent a clinical examination at the study day. Blood pressure (BP) 
was measured in the supine position by an oscillometric sphygmomanometer after a 10-min rest using an 
appropriately sized cuff. Three consecutive measurements were taken, averaging the last two. Blood samples 
were collected to determine glucose, cholesterol, triglycerides, HDL-cholesterol, creatinine, uric acid, and the 
hormonal profile (TSH, GH, ACTH, cortisol, PTH).
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 Estimation and Evaluation of Glomerular Function  
 GFR was measured by the iohexol plasma clearance (mGFR) method.  Briefly, catheters were inserted 
into antecubital veins for injection of the filtration marker and blood sampling. Blood was taken for back-
ground measurement and iohexol standard preparation; a 5 ml i.v. bolus of iohexol (Omnipaque 300; iohexol 
647 mg/ml, corresponding to 300 mg/ml of iodine; Nycomed, Milano, Italy) was then injected within 30 s 
followed by saline solution 10 ml, and blood samples were drawn at 5, 15, 60, 90, 120, 150, 180, 210, 240, and 
300 min. After centrifugation at room temperature (3,000 rpm for 10 min), and plasma separation, iohexol 
 concentrations were determined in duplicate by HPLC (Perkin Elmer, Waltham, MA, USA). Briefly, plasma 
samples were deproteinized with 4 vol 5% perchloric acid and centrifuged twice (13,000 rpm for 5 min). 20 
μl of supernatant were assayed in duplicate through a Pico Tag Column (Waters, Milford, MA, USA), inserting 
a pre-column between the injector and the analytical column. The detector was set at 254 nm, using a mixture 
of deionized water and acetonitrile (96: 4, pH 2.5 with phosphoric acid) as mobile phase, pumped at a rate of 
1.1 ml/min. Iohexol elution from the column was observed after 5 min. As expected, two peaks reflecting its 
isomeric forms in the pharmacological preparation were evident, and the second peak was used for plasma 
clearance calculation. Iohexol concentrations were determined by comparing the peak height of each sample 
with that of the standard curve, obtained by adding known amounts of iohexol to the zero-time plasma sample. 
 DIMSUM, an expert system for multi-exponential model discrimination, was employed to fit plasma 
disappearance curve over time by a 2nd-order model for iohexol concentrations. Elimination constants (α 1 
and α 2 ) and intercepts (A 1 and A 2 ) were used to calculate the area under the disappearance curve (AUC):
AUC = (A 1 /α 1 ) + (A 2 /α 2 ). Plasma iohexol clearance was calculated as the administered dose (double weighing 
of the injection syringe) divided by AUC.
 Values obtained by the above reported technique were compared with the eGFR calculated by the following 
equations: Cockroft-Gault (adjusted by body surface area calculated according to Mosteller formula –
(height (cm) × weight (kg) / 3,600) 0.5 –, MDRD, and CKD-EPI. 
 Measurement of Renal Plasma Flow 
 The whole procedure for measuring the effective renal plasma flow (RPF) was performed according to 
published guidelines  [21] . Two syringes (dose and standard) were prepared with 7 MBq of  123 I-ortho-iodo-
hippurate ( 123 I-OIH Hippuran; Covidien, Dublin, Ireland) and assayed in the dose calibrator to determine the 
actual administered activity. Radiotracer was intravenously administered as bolus; another i.v. line in the 
opposite arm served to withdraw blood samples. To obtain a complete plasma curve, 5 ml blood was drawn at 
5, 10, 15, 20, 30, 40, and 60 min post-injection in anticoagulant citric dextrose tubes. Plasma was centrifuged and 
two 1-ml aliquots were withdrawn for counting. Standard was diluted till 1,000 ml with water, and three count 
vials were obtained. Plasma and standard were counted by an AtomLab 950 (Biodex Medical Systems Inc., 
Shirley, NY, USA). Counts (cpm/ml) from each plasma aliquot and for the three separate standards were averaged.
 Injected dose was calculated by multiplying the final value of the standard corrected for the dilution 
factor by the ratio between activity (MBq) of the injected dose and standard. Multiple blood sample clearance 
curves were fitted with a two-exponential model using the curve fitting tool of the software MatLab 7.9.0 (The 
Mathworks TM ), and RPF was calculated as follows:
 RPF (ml/min) = injected dose/(A/α + B/β) (1), 
 where A and B are the y-axis intercepts of each exponential component and α, and β are the respective 
slopes.
 Baseline and Dynamic Vascular Renal Indices 
 RI was obtained in resting conditions and 5 min after 25 μg of sublingual glyceryl trinitrate (GTN). A 
complete renal scan, including measurement of longitudinal renal diameter, was performed by a single 
trained operator (R.M.B.) with an ultrasound machine (MyLab 25; ESAOTE, Florence, Italy) equipped with a 
high-resolution multifrequency Convex probe (2.5–4.5 MHz). Three velocimetric measurements of the inter-
lobar renal arteries in both kidneys adjacent to medullary pyramids were obtained by a translumbar 
approach. RI was calculated as follows: 
 RI = (systolic peak velocity – end diastolic velocity) / systolic peak velocity  (2).
 Dynamic resistive index was calculated as percent changes from baseline in response to GTN. 
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 Endothelium-Dependent and -Independent Vasodilation in the Brachial Artery 
 Endothelium-dependent vasodilation of the brachial artery was assessed by the flow-mediated dilation 
(FMD) technique, as previously described  [22] . A cuff was positioned around the right forearm; the right 
brachial artery was located and scanned longitudinally 5–10 cm above the elbow using a 10 MHz linear array 
transducer (MyLab 25), maintaining the probe in the same position by a stereotactic clamp. The cuff was then 
inflated at 300 ± 30 mm Hg and deflated after 5 min; response to reactive hyperemia was observed in the 
following 4 min. FMD was calculated as the maximal percent increase in diameter above baseline (mean of 
1-min recordings). Brachial artery diameter was measured by a real-time computerized edge detection 
system, allowing simultaneous continuous measurements of brachial artery diameter and flow velocity 
(Cardiovascular Suite; Quipu srl, Pisa, Italy).
 Arterial Tonometry 
 Carotid-femoral pulse wave velocity (PWV) was assessed by arterial tonometry (SphygmoCor, AtCor 
Medical, West Ryde, Australia), according to international recommendations  [23] . PWV was calculated as the 
ratio of the direct femoral-carotid distance, multiplied by 0.8 and wave transit time. Radial waveform was 
also acquired to obtain aortic pressure waveform by means of a validated transfer function on three successive 
measurements. Augmented pressure (AP) was calculated as difference between the second and the first 
systolic peak, and augmentation index (AIx) as the ratio between augmented pressure and pulse pressure, 
normalized at 75 bpm heart rate. 
 Analytical Determinations 
 Plasma glucose was measured by the hexokinase method. Values from OGTT were used to evaluate the 
AUC and the incremental area under the curve (IncrAUC). Cholesterol and triglycerides were determined by 
enzymatic colorimetric assays; HDL cholesterol was measured enzymatically. LDL cholesterol was calculated 
by Friedewald formula. Blood cell count and liver enzymes were measured by routine methods. The uricase/
PAP method and a modified Jaffé method were used for uric acid and creatinine determination, respectively. 
 Serum FT4, FT3, TSH, PTH and 25(OH)vitamin D were measured by immunoradiometric assays 
(DiaSorin, Saluggia, Italy). Cortisol was assessed by chemiluminescent microparticle immunoassay tech-
nology (ARCHITECT ® , Abbott Laboratories, Chicago, IL, USA); ACTH via Immunoradiometric Assay (Nichols 
Institute Diagnostics, San Juan Capistrano, CA, USA). GH was measured by automated chemiluminescent GH 
assay (DiaSorin); its sensitivity was 0.05 μg/l; intra- and inter-assay CV were 4.1 and 7.3% respectively.
 Statistical Analysis 
 All values are expressed as mean ± SD, unless otherwise specified. mGFR obtained by the iohexol tech-
nique was compared with eGFR calculated by Cockroft-Gault, MDRD, and CKD-EPI equations using Pearson’s 
coefficient (R); a Bland-Altman analysis was also performed  [24] and bias calculated. Bland-Altman plots 
were obtained by Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA). Comparisons were performed 
using the nonparametric Mann-Whitney U-test or the unpaired t-test, for variables with non-normal or 
normal distribution. Clinical, hormonal, and hemodynamic correlates of mGFR were assessed using Spear-
man’s rank correlation and multiple linear regression analysis. A p value < 0.05 was considered significant. 
Analyses were performed using NCSS8 software (NCSS, Kaysville, UT, USA). 
 Results 
 Comparison between mGFR and eGFR 
 Clinical characteristics of the study participants are shown in  table 1 . All patients had 
normal fasting glucose and BP values; female gender prevailed; 16% of the participants were 
smokers. 
 Table 2 reports renal functional parameters and the hormonal profile of the study partic-
ipants . mGFR did not significantly differ when compared to that obtained in a group of 10 
healthy individuals with normal BMI that served as internal reference (102.33 ± 14.96 vs. 
105.95 ± 13.36 ml/min/1.73 m 2 ). When compared with mGFR, the estimation formula with 
the best performance was the CKD-EPI (R = 0.49, p = 0.0003); this was also true in subjects 
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with mGFR below the median value (i.e., 104.20 ml/min/1.73 m 2 ) (R = 0.59, p = 0.0027; 
 table 3 ). 
 Figure 1 shows Bland-Altman plots comparing mGFR with the three GFR estimation 
formulae. Bland-Altman analysis provided an unadjusted bias of –96.1 (–37.7 ml/min/1.73 
m 2 ) for Cockroft-Gault, 11.3 ml/min/1.73 m 2 for MDRD, and 5.3 ml/min/1.73 m 2 for CKD-EPI. 
The standard deviation of the difference was equal to 57.5 (–34.2 ml/min/1.73 m 2 ) for 
Age, years 44.2 ± 11.8
Gender (M/F) 19/31
Smokers (n) 8
BMI, kg/m2 45.98 ± 6.98
Systolic blood pressure, mm Hg 136.1 ± 5.3
Diastolic blood pressure, mm Hg 81.6 ± 5.4
Albumin excretion rate, mg/24 h 5.6 (4.0–8.2)
Fasting blood glucose, mg/dl 95.2 ± 18.4
Total cholesterol, mg/dl 185.1 ± 30.6
HDL cholesterol, mg/dl 44.9 ± 11.1
LDL cholesterol, mg/dl 114.1 ± 24.8
Triglycerides, mg/dl 153.4 ± 80.7
Lp(a), mg/dl 16.2 ± 17.6
BUN, mg/dl 14.8 ± 2.9
Uric acid, mg/dl 5.77 ± 1.49
AST, IU/l 27.8 ± 13.8
ALT, IU/l 34.8 ± 17.3
γGT, IU/l 30.4 ± 16.7
Fibrinogen, mg/dl 344.7 ± 52.8
RBC (n/mmc) 4.71 ± 0.37
Hb, g/dl 13.4 ± 1.4
WBC (n/mmc) 7.19 ± 1.86
Platelets (n/mmc) 262 ± 50
 Table 1.  Clinical characteristics 
of obese individuals. Data are 
expressed as mean ± SD, median 
(IQ range) or number and %.
 Table 2.  Measured and estimated (according to MDRD, CKD-EPI and Cockroft-Gault algorithms) glomerular 
filtration rate and hormone pattern in the whole study cohort (n = 50) and divided into above (n = 26) and 
below (n = 24) the median mGFR value (104.20 ml/min/1.73 m2)a
Para meters (normal range) All Above Below p value
True GFR 102.33 ± 14.96 113.91 ± 5.61 89.78 ± 11.26 <0.001
eGFR (MDRD) 91.05 ± 20.55 96.71 ± 15.60 84.91 ± 23.65 0.041
eGFR (CKD-EPI) 97.05 ± 17.08 102.06 ± 12.87 91.63 ± 19.55 0.030
eGFR (Cockroft-Gault) 140.07 ± 36.20 148.71 ± 30.59 130.70 ± 39.98 0.079
GH, ng/ml (0.03–0.97) 0.14 ± 0.10 0.13 ± 0.10 0.15 ± 0.11 0.574
TSH, μU/ml (0.4–4.0) 1.72 ± 1.15 1.73 ± 0.99 1.69 ± 1.37 0.918
fT3, pg/ml (1.8–4.8) 3.57 ± 0.69 3.72 ± 0.67 3.41 ± 0.68 0.118
fT4, ng/dl (0.8–1.8) 0.99 ± 0.20 0.96 ± 0.22 1.03 ± 0.18 0.198
ACTH, pg/ml (<50) 40.42 ± 21.80 44.10 ± 25.22 36.43 ± 17.01 0.218
Cortisol 8 am, μg/dl (6.7–22.6) 19.50 ± 9.27 17.41 ± 9.47 21.75 ± 8.69 0.098
Cortisol 4 pm, μg/dl (<10.0) 11.81 ± 5.01 11.09 ± 3.95 12.68 ± 6.06 0.312
PTH, pg/ml (8–80) 54.50 ± 29.31 46.23 ± 24.24 63.46 ± 32.09 0.036
25(OH)D3, ng/ml (11–70) 17.45 ± 10.72 20.51 ± 12.68 14.13 ± 6.93 0.034
Folate, ng/ml (4.6–18.7) 5.45 ± 1.80 5.39 ± 1.61 5.52 ± 2.02 0.799
Vitamin B12, pg/ml (191–663) 385.7 ± 143.3 379.23 ± 130.68 392.67 ± 158.37 0.744
 aData are expressed as mean ± SD.
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Cockroft-Gault, 19.2 ml/min/1.73 m 2 for MDRD, and 16.2 ml/min/1.73 m 2 for CKD-EPI. The 
difference between Cockroft-Gault and mGFR was directly and significantly related to the 
average between the two measurements (R = –0.73, p < 0.001), indicating that overestimation 
by Cockroft-Gault is greater for higher GFR. 
 Correlates of mGFR  
 mGFR was higher in men than in women (108 ± 13 vs. 98 ± 15 ml/min/1.73 m 2 , p = 0.015) 
but was not related to age, BMI, serum creatinine, and brachial or central BP values. On the 
contrary, an interesting linear relationship emerged between mGFR and the total AUC (R = 
0.36, p = 0.009) and IncrAUC of glucose (R = 0.32, p = 0.02). Furthermore, mGFR was corre-
lated inversely with HDL cholesterol (R = –0.29, p = 0.04). 
 The hormonal profile of the study population is shown in  table 2 . Mean values were all 
within the normal range, even though with the noticeable tendency to low GH and folate and 
high cortisol levels. No relationships between hormonal pattern and mGFR emerged, except 
for an inverse linear relationship with PTH (R = –0.319, p = 0.024) and with h8 cortisol (R = 
–0.31, p = 0.03). A trend was observed with vitamin D. Comparing patients with mGFR above 
Intercept (t) R p value
All
True/MDRD 8.278 0.450 0.0010
True/CKD/EPI 5.572 0.493 0.0003
True/Cockroft 10.199 0.336 0.0171
Above median value
True/MDRD 15.333 0.138 0.5005
True/CKD/EPI 12.279 0.039 0.8509
True/Cockroft 21.163 0.166 0.4163
Below median value
True/MDRD 8.974 0.477 0.0184
True/CKD/EPI 6.314 0.585 0.0027
True/Cockroft 9.989 0.406 0.049
 Table 3.  Correlation (Pearson’s 
R) between mGFR and different 
estimation formulae in the study 
population as a whole (n = 50) 
and divided into above (n = 26) 
and below (n = 24)  the median 
mGFR value (104.20 ml/
min/1.73 m2)
 Fig. 1. Bland-Altman plots comparing mGFR with eGFR by  a Cockroft-Gault formula;  b CKD-EPI formula;  c 
MDRD formula. Black lines represent bias, while dotted lines represent ± 2 standard deviations. 
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and below the median, the latter had significantly higher PTH levels (p = 0.036), and lower 
vitamin D3 (p = 0.034).
 Table 4 shows the renal ultrasonographic measures in obese patients as a whole and 
according to the median mGFR value. Renal longitudinal diameter (mean value between right 
and left kidney) was significantly higher in patients above the median mGFR, with a linear 
correlation between the two parameters in the whole group (R = 0.57, p = 0.0009). Neither 
basal nor dynamic RI were related with mGFR, even if there was a small but significantly 
higher RI in those above the median mGFR value. Neither FMD nor PWV and wave reflection 
variables showed any relationship with mGFR.
 Multiple regression analysis, aimed to evaluate independent determinants of mGFR in 
these morbidly obese individuals, was performed, testing each variable significantly asso-
ciated with mGFR in the univariate analysis: IncrAUC, blood urea nitrogen (BUN), renal 
diameter, and RPF remained significantly associated with mGFR ( table 5 ). In a further, fully 
adjusted model including IncrAUC, BUN, renal diameter and RPF together with age, sex and 
BMI, only renal diameter and RPF remained independently related with mGFR (full model R 2 
= 0.67), accounting for 15% and 21% of mGFR variance, respectively.
 Correlates of Measured Renal Plasma Flow  
 In the subset of 25 patients receiving the measurement of RPF (mean 609.14 ± 156.14 
ml/min), it was significantly higher in those with mGFR  ≥ 104.2 ml/min/1.73 m 2 (710.39 ± 
 Table 4.  Main ultrasonographic parameters in obese individuals as a whole (n = 50) and divided into above 
(n = 26) and below (n = 24) the median mGFR value (104.20 ml/min/1.73 m2)a
All Above Below p value
Brachial artery diameter, mm 4.26 ± 0.73 4.37 ± 0.95 4.14 ± 0.41 0.493
Renal longitudinal diameter, mm 11.634 ± 1.087 12.093 ± 1.108 11.176 ± 0.878 0.022
Aortic PWV, m/s 8.24 ± 1.22 8.20 ± 0.99 8.27 ± 1.50 0.892
FMD, % 4.54 ± 2.41 4.20 ± 2.30 4.89 ± 2.58 0.534
Augmentation index 18.09 ± 1.79 18.42 ± 8.63 17.73 ± 8.92 0.852
Renal RI 0.62 ± 0.05 0.64 ± 0.05 0.60 ± 0.04 0.029
DRIN –5.70 ± 4.68 –5.23 ± 4.60 –6.22 ± 4.92 0.606
 aData are expressed as mean ± SD.
 Table 5.  Univariate and multivariate linear regression exploring variables associated with mGFR
Variable Univariate linear regression Multivariate linear regression  
(adjusted for age, sex, BMI)
R p value R2 full m odel standardized 
coefficient
p value
BUN –0.31 0.03 0.22 –0.31 0.03
IncrAUC 0.32 0.02 0.22 0.30 0.03
HDL cholesterol –0.29 0.04 0.15 –0.11 0.45
PTH –0.32 0.02 0.18 –0.24 0.10
h8 Cortisol –0.31 0.03 0.15 –0.13 0.36
Renal diameter 0.57 0.0009 0.38 0.41 0.02
RPF 0.49 0.02 0.45 0.67 0.005
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176.59 vs. 555.13 ± 117.20 ml/min; p = 0.02). As expected, RPF was directly correlated with 
mGFR (R = 0.49, p = 0.02). RPF tended to be related with age (R = –0.36, p = 0.09), systolic BP 
(R = 0.38, p = 0.08) and creatinine (R = –0.35, p = 0.09). Interestingly, it was also related to 
GH (R = –0.43, p = 0.04), even though this correlation lost significance after adjustment for 
age, sex, and BMI (p = 0.17, standardized coefficient = –0.28, full model R 2 = 0.38). Among 
vascular parameters, the only significant relation was between RPF and AIx (R = 0.47, p = 
0.03), remaining significant even after adjustment for age, sex, and BMI (p = 0.03, standardized 
coefficient = 0.53, full model R 2 = 0.48). 
 Mean filtration fraction was 17 ± 4%, being similar in subjects above and below the 
median values. It correlated directly with age, systolic BP and renal diameter (R = 0.74; p < 
0.001) and inversely with BMI, heart rate and, obviously, RPF (R = –0.73; p < 0.0001). 
 Discussion 
 The main novelties of the present study are: i) among formulae commonly used for esti-
mating GFR, CKD-EPI shows the best performance respect to true GFR measurements in 
morbidly obese individuals with preserved renal function and no metabolic comorbidities; ii) 
glucose level increments during an OGTT are correlated to hyperfiltration; and iii) renal 
diameter and PTH are independent determinants of mGFR.
 Previous studies have documented the unreliability of algorithms to estimate glomerular 
function in patients with obesity and diabetes, especially when suffering from CKD  [25] , but 
such comparisons in severely obese otherwise healthy individuals are scanty. We demon-
strated that CKD-EPI has the best correlation with mGFR (data adjusted by surface area) with 
the lowest bias, as recently reported by Friedman et al.  [26] , and this was also true in the high 
range of GFR. Indeed, CKD-EPI was the only estimation formula with no increase in bias with 
increasing values of mGFR. 
 Noticeably, mean GFR value obtained in our patients is fully superimposable to that 
measured by Cr-EDTA technique in a subset of morbidly obese nondiabetic individuals  [27] . 
Previous reports showed the largest influence of BMI on overestimation of GFR for Cockcroft-
Gault formula, with less influence on MDRD and CKD-EPI  [28] ; which does not come as a 
surprise as body weight is a component of formula itself. Other differences reside in the fact 
that previous reports evaluated obese patients with various degrees of renal impairment  [29] 
while, in our study population, none showed micro- or macroalbuminuria or had GFR < 60 
ml/min/1.73 m 2 . 
 We also addressed the thus far unsolved question whether estimation formulae can be 
adequately used for any threshold of BMI by comparing true and eGFR measures in severely 
obese people with preserved renal function, confirming a good accuracy also in people with 
BMI > 40 kg/m 2 . 
 In type 2 diabetes and in pre-diabetic states, uncontrolled blood glucose levels are 
proportionately related to the severity of hyperfiltration, even after adjustment for 
confounding factors  [30, 31] . The observation of total AUC and IncrAUC of glucose as clinical 
correlates of increased GFR in obese nondiabetic individuals points to a continuum of athero-
sclerotic risk factors, suggesting that fluctuations of glucose levels, which are more likely in 
the post-prandial phase, may act as determinant of glomerular hyperfiltration in obesity.
 In the subset of individuals receiving also a measurement of RPF, we observed a strong 
linear correlation between GFR and RPF, with no apparent reduction of the filtration fraction 
in patients with so far fully preserved renal function, which was also confirmed by the fact 
that all were normoalbuminuric. 
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 We did not find any relation between mGFR and BP or parameters of vascular function 
and structure in our study group. In contrast to previous cross-sectional studies in popula-
tions without CKD that did not find any correlation between eGFR and PWV  [32, 33] , in our 
population PWV and diastolic BP were significantly correlated with CKD-EPI (R = –53, p = 
0.01 and R = –0.33, p = 0.02 respectively), but not with mGFR, suggesting that the CKD-EPI 
formula might depict vascular age beyond renal function, possibly due to the inclusion of age 
and sex in the formula. Commenting on the results of vascular variables, the relationship 
between Aix75, as a marker of wave reflection, and RPF deserves further attention. This 
finding suggests that in morbid obesity a hypertrophic renal vascular bed might enhance 
wave reflection, which could be associated with negative consequences on cardiovascular 
prognosis  [34] .
 A novel approach of our study was to correlate  true GFR and RPF with a complete 
hormonal pattern in severely obese patients. As expected  [35] , these individuals showed GH 
levels in the low normal range. Consequently there was no correlation with mGFR, suggesting 
as only a marked GH hypersecretion, like in acromegaly, may affect glomerular hyperfil-
tration  [36] . Interestingly, the well-known inverse relationship between PTH and GFR as well 
as the relationship between vitamin D and GFR seem to be confirmed in morbidly obese indi-
viduals also in the presence of a fully preserved renal function, with a tendency to a slightly 
lower PTH and higher vitamin D levels in those with mGFR above the median value.
 In conclusion, our study validates CKD-EPI as the best formula when compared to a true 
measure of GFR in severely obese people with preserved renal function and shows that 
glucose level increments during an OGTT are correlated to hyperfiltration. Its major limita-
tions reside in the small size of the cohort and in its cross-sectional nature that does not allow 
to draw any conclusions regarding the potential long-term effect of even minor impairments 
of hormone patterns on long-term renal function.
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